{"id":"W4414443225","doi":"10.1080/14728214.2025.2565189","title":"Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape","year":2025,"lang":"en","type":"review","venue":"Expert Opinion on Emerging Drugs","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Clinical trial; Myelin oligodendrocyte glycoprotein; Multiple sclerosis; Immunotherapy; Clinical neurology; Targeted therapy; Disease; MEDLINE","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00678491,0.0006490329,0.002414115,0.001157609,0.0002756631,0.001780066,0.001387701,0.002358104,0.00821988],"category_scores_gemma":[0.01032383,0.0002409983,0.001642354,0.001306466,0.0006070333,0.002215735,0.0007056493,0.00276312,0.001811553],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001198348,"about_ca_system_score_gemma":0.00401293,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008573372,"about_ca_topic_score_gemma":0.002430495,"domain_scores_codex":[0.9979092,0.001105957,0.0002834905,0.0001682425,0.0004359856,0.00009708274],"domain_scores_gemma":[0.9911203,0.006153001,0.0008762237,0.0001306106,0.001444708,0.0002751919],"domain_codex":null,"domain_gemma":"methods","domain_candidate":"methods","domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0005709099,0.00009253703,0.0001572048,0.06635488,0.0004044333,0.0000938064,0.00007659972,0.0002970258,0.0007276054,0.005444279,0.04183401,0.8839468],"study_design_scores_gemma":[0.001005085,0.0007276887,0.0009097601,0.129758,0.001638227,0.000582926,0.0001656507,0.0003145961,0.0004536142,0.006953532,0.8574503,0.00004053461],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001501926,0.9945008,0.0001754654,0.003601277,0.0004571532,0.00004295558,0.00005276537,0.00001104753,0.001008411],"genre_scores_gemma":[0.001981927,0.9916897,0.0007136022,0.004217037,0.0006431706,0.00013345,0.0001051579,0.000007505168,0.0005084604],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9932151,"threshold_uncertainty_score":0.03588247,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1193818646769692,"score_gpt":0.4944612600731487,"score_spread":0.3750793953961795,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}